Roche sued for possible contamination at Nutley site; Particle Sciences expands sterile operations;

> A $20 million manufacturing investment has been credited by Bharat Biotech as playing a large part in its ability to bring a new rotavirus to market for under a $1 a dose. Story

> A threatened lawsuit has been filed by two residents of Nutley, NJ, claiming that a Roche ($RHHBY) facility there contaminated groundwater before it closed at the end of 2013. Story

> The FDA is asking the public to weigh in on drug compounding. Report

> Bethlehem, PA-based drug developer Particles Sciences is expanding its sterile and aseptic manufacturing capacity, including for nano-milled drug products. Report

> Howard Sklamberg, FDA deputy commissioner for global regulatory operations and policy, Cynthia Schnedar, director, office of compliance and Michael Taylor, deputy commissioner for foods and veterinary medicine, will go to India this month to finalize an agreement of cooperation between the two countries. Story

> Dr. Reddy's is reportedly in discussions to buy the India business of Belgian drugmaker UCB for $135 million. Story

And Finally... Dr. Reddy's Custom Pharmaceutical Services (CPS) has a new formulation development laboratory in Hyderabad where it is combining its active pharmaceutical ingredients development team with its formulation teams for efficiency. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.